

WE CLAIM:

1. A method for modulating triglyceride levels in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
2. The method according to claim 1 wherein said exendin or exendin agonist is administered continuously.
3. The method according to claim 1 wherein said administration is by injection.
4. The method according to claim 3 wherein the injection is a subcutaneous injection.
5. The method according to claim 1 wherein about 1  $\mu$ g-30 $\mu$ g to about 1 mg of the exendin or exendin agonist is administered per day.
6. The method according to claim 1 wherein about 1  $\mu$ g-30  $\mu$ g to about 500  $\mu$ g of the exendin or exendin agonist is administered per day.
7. The method according to claim 1 wherein about 1  $\mu$ g-30  $\mu$ g to about 100  $\mu$ g of the exendin or exendin agonist is administered per day.
8. The method according to claim 1, wherein about 3  $\mu$ g to about 50  $\mu$ g of the exendin or exendin agonist is administered per day.
9. The method of claim ~~1~~ wherein said subject is human.
10. A method for modulating plasma triglyceride concentrations in a subject with heart disease comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.
11. The method according to any of claims 1-10 wherein said exendin is exendin-3.

12. The method according to any of claims 1-10 wherein said exendin is exendin-4.

13. The method according to any of claims 1-10 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.

14. The method according to any of claims 1-10 wherein said exendin agonist is an exendin analog or derivative.

15. The method according to any of claims 1-10, further comprising administering a therapeutically effective amount of a statin.

16. The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula I.

17. The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula II.

18. The method according to any of claims 1-10 wherein said exendin agonist is an exendin agonist according to Formula III.

19. A method for treating dyslipidemia in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

20. The method according to claim 19 wherein said exendin agonist is an exendin analog or derivative.

21. The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula I.

22. The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula II.

23. The method according to claim 19 wherein said exendin agonist is an exendin agonist according to Formula III.

24. A method for modulating postprandial triglyceride levels in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist.

25. The method according to claim 24 wherein said exendin or exendin agonist is administered continuously.

26. The method according to claim 24 wherein said administration is by injection.

27. The method according to claim 26 wherein the injection is a subcutaneous injection.

28. The method according to claim 24 wherein about 1  $\mu$ g-30 $\mu$ g to about 1 mg of the exendin or exendin agonist is administered per day.


29. The method according to claim 24 wherein about 1  $\mu$ g-30  $\mu$ g to about 500  $\mu$ g of the exendin or exendin agonist is administered per day.

30. The method according to claim 24 wherein about 1  $\mu$ g-30  $\mu$ g to about 100  $\mu$ g of the exendin or exendin agonist is administered per day.

31. The method according to claim 24, wherein about 3  $\mu$ g to about 50  $\mu$ g of the exendin or exendin agonist is administered per day.

32. The method of claim 24 wherein said subject is human.

33. The method according to any of claims 24-32 wherein said exendin is exendin-3.
34. The method according to any of claims 24-32 wherein said exendin is exendin-4.
35. The method according to any of claims 24-32 wherein said exendin agonist is selected from the group consisting of exendin-4 acid, exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide, <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4, and <sup>14</sup>Leu, <sup>25</sup>Phe exendin-4 (1-28) amide.
36. The method according to any of claims 24-32 wherein said exendin agonist is an exendin analog or derivative.
37. The method according to any of claims 24-32, further comprising administering a therapeutically effective amount of a statin.
38. The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula I.
39. The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula II.
40. The method according to any of claims 24-32 wherein said exendin agonist is an exendin agonist according to Formula III.

A handwritten signature in black ink, appearing to be 'B. G. G.' or similar, with a long, sweeping underline.